Company: INDP
Filing Date: 2025-05-14
Form Type: 10-Q
Source: 0001641172-25-010099
Chunk: 26

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-05-14
Form: 10-Q
Item: Part I, Item 1
Chunk 26
---
613) 
     (60,439,183)

    Total stockholders’ equity 
     2,799,731  
     3,944,875 

    Total liabilities and stockholders’ equity 
    $5,411,622  
    $7,338,756 

See accompanying notes to the unaudited condensed consolidated
financial statements

F-1

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Operations

    2025  
    2024 

    Three Months  Ended March 31, 

    2025  
    2024 
  
    Operating expenses: 

    Research and development 
    $2,810,840  
    $1,591,142 
  
    General and administrative 
     1,761,719  
     2,352,097 

    Total operating expenses 
     4,572,559  
     3,943,239 

    Loss from operations 
     (4,572,559) 
     (3,943,239)

    Other income, net 
     40,129  
     136,562 

    Net loss 
    $(4,532,430) 
    $(3,806,677)

    Net loss available to common stockholders per share of common stock, basic and diluted 
    $(0.32) 
    $(0.45)

    Weighted average number of shares used in calculating net loss per share, basic and diluted 
     14,102,378  
     8,442,364 

See accompanying notes to the unaudited condensed consolidated
financial statements

F-2

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Stockholders’
Equity

    Shares  
    Amount  
    Capital  
    deficit  
    Total 

    Common stock  
    Additional 
paid in  
    Accumulated  

    Shares  
    Amount  
    Capital  
    deficit  
    Total 

    Balance, January 1, 2024 
     8,401,047  
    $84,011  
    $57,409,643  
    $(45,417,156) 
    $12,076,498 
  
    Stock-based compensation 
     -